Bladder conservation treatment in the elderly population: Results and prognostic factors of muscle-invasive bladder cancer

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 32, Issue 4, 2009, Pages 333-337

  Tran, Eric ^a   Souhami, Luis ^a   Tanguay, Simon ^a   Rajan, Raghu ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Bladder cancer; Chemotherapy; Conservative treatment; Elderly; Radiotherapy

Indexed keywords

CISPLATIN; FLUOROURACIL;

AGED; AGING; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER INVASION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CAUSE SPECIFIC SURVIVAL; CLINICAL ARTICLE; CONSERVATIVE TREATMENT; CYSTECTOMY; DISEASE CONTROL; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HUMAN; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PROGNOSIS; SUPERFICIAL CANCER; TRANSURETHRAL RESECTION; UNIVARIATE ANALYSIS; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; COHORT STUDIES; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; FEMALE; GERIATRIC ASSESSMENT; HUMANS; KAPLAN-MEIERS ESTIMATE; MALE; NEOPLASM INVASIVENESS; NEOPLASM STAGING; ORGAN PRESERVATION; PROBABILITY; PROGNOSIS; QUALITY OF LIFE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SURVIVAL ANALYSIS; URINARY BLADDER NEOPLASMS;

EID: 69349099232     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31818b9486     Document Type: Article

References (28)

1. Kotake T. [Chemotherapy of invasive bladder cancer]. Gan To Kagaku Ryoho. 1991;18:2375-2382.
2. Goffinet DR, Schneider MJ, Glatstein EJ, et al. Bladder cancer: results of radiation therapy in 384 patients. Radiology. 1975;117:149-153.
3. Shipley WU, Rose MA, Perrone TL, et al. Full-dose irradiation for patients with invasive bladder carcinoma: clinical and histological factors prognostic of improved survival. J Urol. 1985;134:679-683.
4. Henry K, Miller J, Mori M, et al. Comparison of transurethral resection to radical therapies for stage B bladder tumors. J Urol. 1988;140:964-967. (Pubitemid 18271977)
5. Roosen JU, Geertsen U, Jahn H, et al. Invasive, high grade transitional cell carcinoma of the bladder treated with transurethral resection. A survival analysis focusing on TUR as monotherapy. Scand J Urol Nephrol. 1997;31:39-42. (Pubitemid 27105239)
6. Dunst J, Sauer R, Schrott KM, et al. Organ-sparing treatment of advanced bladder cancer: a 10-year experience. Int J Radiat Oncol Biol Phys. 1994;30:261-266. (Pubitemid 24309726)
7. Housset M, Maulard C, Chretien Y, et al. Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder: a prospective study. J Clin Oncol. 1993;11:2150-2157. (Pubitemid 23332251)
8. Kachnic LA, Kaufman DS, Heney NM, et al. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997;15:1022-1029. (Pubitemid 27106286)
9. Kaufman DS, Winter KA, Shipley WU, et al. The initial results in muscleinvading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response. Oncologist. 2000;5:471-476.
10. Rodel C, Grabenbauer GG, Kuhn R, et al. Combined-modality treatment and selective organ preservation in invasive bladder cancer: long-term results. J Clin Oncol. 2002;20:3061-3071. (Pubitemid 34791095)
11. Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998;16:3576-3583.
12. Tester W, Caplan R, Heaney J, et al. Neoadjuvant combined modality program with selective organ preservation for invasive bladder cancer: results of Radiation Therapy Oncology Group phase II trial 8802. J Clin Oncol. 1996;14:119-126. (Pubitemid 26020004)
13. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
14. Prout GR, Marshall VF. The prognosis with untreated bladder tumors. Cancer. 1956;9:551-558.
15. Rodel C. Current status of radiation therapy and combined-modality treatment for bladder cancer. Strahlenther Onkol. 2004;180:701-709. (Pubitemid 40022277)
16. Kim HL, Steinberg GD. The current status of bladder preservation in the treatment of muscle invasive bladder cancer. J Urol. 2000;164:627-632. (Pubitemid 30637589)
17. Brendler CB, Steinberg GD, Marshall FF, et al. Local recurrence and survival following nerve-sparing radical cystoprostatectomy. J Urol. 1990;144:1137-1140; discussion 1140-11131
18. Raghavan D, Huben R. Management of bladder cancer. Curr Probl Cancer. 1995;19:1-64.
19. Frazier HA, Robertson JE, Dodge RK, et al. The value of pathologic factors in predicting cancer-specific survival among patients treated with radical cystectomy for transitional cell carcinoma of the bladder and prostate. Cancer. 1993;71:3993-4001.
20. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43-66.
21. Cohen SM, Johansson SL. Epidemiology and etiology of bladder cancer. Urol Clin North Am. 1992;19:421-428.
22. Nielsen ME, Shariat SF, Karakiewicz PI, et al. Advanced age is associated with poorer bladder cancer-specific survival in patients treated with radical cystectomy. Eur Urol. 2007;51:699-708.
23. Goffin JR, Rajan R, Souhami L. Tolerance of radiotherapy and chemotherapy in elderly patients with bladder cancer. Am J Clin Oncol. 2004;27:172-177. (Pubitemid 38451480)
24. Lorusso V, Pollera CF, Antimi M, et al. A phase II study of gemcitabine in patients with transitional cell carcinoma of the urinary tract previously treated with platinum. Italian Co-operative Group on Bladder Cancer. Eur J Cancer. 1998;34:1208-1212.
25. Moore MJ, Tannock IF, Ernst DS, et al. Gemcitabine: a promising new agent in the treatment of advanced urothelial cancer. J Clin Oncol. 1997;15:3441-3445. (Pubitemid 27527715)
26. Pollera CF, Ceribelli A, Crecco M, et al. Weekly gemcitabine in advanced bladder cancer: a preliminary report from a phase I study. Ann Oncol. 1994;5:182-184. (Pubitemid 24062575)
27. Nutting CM, Convery DJ, Cosgrove VP, et al. Reduction of small and large bowel irradiation using an optimized intensity-modulated pelvic radiotherapy technique in patients with prostate cancer. Int J Radiat Oncol Biol Phys. 2000;48:649-656.
28. Zelefsky MJ, Fuks Z, Happersett L, et al. Clinical experience with intensity modulated radiation therapy (IMRT) in prostate cancer. Radiother Oncol. 2000;55:241-249. (Pubitemid 30408370)